Eli Lilly's oncology R&D spree continues with $576M deal to buy a startup and reel back Aurora A drug
Eli Lilly’s oncology deal spree is continuing this morning with a $576 million deal to buy out a Montreal-based startup and reel back in an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
